Company Overview and News

32
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-10-03 sec.gov - 20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLRB

18
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-10-02 sec.gov - 6
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CLRB

18
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-09-25 sec.gov - 6
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

19
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-09-24 sec.gov - 7
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLRB

18
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-09-17 sec.gov - 6
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLRB

13
Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer

2018-09-17 marketwatch - 1
Cellectar Biosciences Inc. CLRB, -2.23% said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children called osteosarcoma. The treatment, CLR 131, is the company's lead Phospholipid Drug Conjugate(TM) (PDC) product candidate, which delivers radiation directly to cells. "CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers," said John Friend, M.
CLRB CLRBZ CLRBW

13
Cellectar Biosciences stock surges 23% premarket

2018-09-17 marketwatch - 1
Cellectar Biosciences Inc. said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children called osteosarcoma. The treatment, CLR 131, is the company's lead Phospholipid Drug Conjugate(TM) (PDC) product candidate, which delivers radiation directly to cells. "CLR 131 has demonstrated promise as an anticancer agent in preclinical and clinical settings, and we are working now to establish its impact on various rare and deadly pediatric cancers," said John Friend, M.
CLRB CLRBZ CLRBW

12
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

2018-09-17 globenewswire
MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to CLR 131 for the treatment of osteosarcoma, a rare pediatric cancer.
CLRB CLRBZ CLRBW

21
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-09-06 sec.gov - 9
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________
CLRB

14
Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-29 globenewswire - 2
MADISON, Wis., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that James Caruso, president and chief executive officer of Cellectar Biosciences, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.
CLRB CLRBZ CLRBW

12
CLRB / Cellectar Biosciences, Inc. null

2018-08-24 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C<@,"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S$Y [email protected] [email protected],C
CLRB

12
CLRB / Cellectar Biosciences, Inc. null

2018-08-24 sec.gov
CELLECTAR BIOSCIENCES, INC. 3301 Agriculture Drive Madison, WI 53716 July 25, 2018
CLRB

12
CLRB / Cellectar Biosciences, Inc. null

2018-08-24 sec.gov
Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34108 J
CLRB

12
CLRB / Cellectar Biosciences, Inc. FORM 8-K (Current Report)

2018-08-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLRB

12
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

2018-08-20 globenewswire
Positive Results from Cohort 5 of Phase 1b Trial Company Intends to Initiate a Sixth Cohort and Transition Ongoing Phase 2 Trial to a Fractionated Dose
CLRB CLRBZ CLRBW

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 15117F302